FAQ/Help |
Calendar |
Search |
Today's Posts |
08-20-2019, 09:27 AM | #1 | ||
|
|||
Member
|
Trial of Parkinson's Cell Therapy to Follow Bayer Acquistion of BlueRock Therapeutics
Its lead program is in Parkinson’s, where preclinical work using BlueRock’s induced pluripotent stem cell (iPSC) technology has shown motor function improvement and higher dopamine production by stem cell-derived dopamine-producing neurons — those that are typically lost in distinct brain regions of Parkinson’s patients. Also: Parkinson's Gene Therapy in Clinical Trial, AXO-Lenti-PD, Safe And Effective in Monkey Model of Disease, Study Says Last edited by ashleyk; 08-20-2019 at 09:33 AM. Reason: more info |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Adult cells transformed into early-stage nerve cells, bypassing the pluripotent stem | Parkinson's Disease | |||
Embryonic Stem Cells—and Other Stem Cells—Promise to Advance Treatments | Parkinson's Disease | |||
UCLA stem cells scientists make electrically active motor neurons from iPS cells | ALS News & Research | |||
Stem cells may enhance capability of heart cells to regenerate | ALS News & Research | |||
Stem cells become Adult stem cells about a month after birth,,,Wow | Parkinson's Disease |